Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past to Help Discover Long-Acting Oral Drugs in the Future

Paul W. Smith, Fabio Zuccotto, Robert H. Bates, Maria Santos Martinez-Martinez, Kevin D. Read, Caroline Peet, Ola Epemolu

Research output: Contribution to journalArticle

2 Citations (Scopus)
91 Downloads (Pure)

Abstract

β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.

Original languageEnglish
Pages (from-to)1439-1447
Number of pages9
JournalACS Infectious Diseases
Volume4
Issue number10
Early online date24 Aug 2018
DOIs
Publication statusPublished - 12 Oct 2018

Fingerprint

Lactams
Pharmacokinetics
Anti-Bacterial Agents
Pharmaceutical Preparations
Drug Discovery
Tuberculosis
Research

Keywords

  • carbapenem
  • cephalosporin
  • M. tuberculosis
  • penicillin
  • pharmacokinetics
  • β-lactam

Cite this

@article{81685fe7880f4be1b7131098c5b5ea49,
title = "Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past to Help Discover Long-Acting Oral Drugs in the Future",
abstract = "β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.",
keywords = "carbapenem, cephalosporin, M. tuberculosis, penicillin, pharmacokinetics, β-lactam",
author = "Smith, {Paul W.} and Fabio Zuccotto and Bates, {Robert H.} and Martinez-Martinez, {Maria Santos} and Read, {Kevin D.} and Caroline Peet and Ola Epemolu",
note = "The authors gratefully acknowledge funding provided for this work by the Bill and Melinda Gates Foundation (BMGF, supporting P.W.S.) and the Wellcome Trust (Centre Award 203134/Z/16/Z supporting F.Z., K.D.R., C.P., and O.E.; Grant Award 100195/Z/12/Z supporting F.Z.). The authors would like to thank John Dixon (JD International Consulting Ltd) and Peter Warner (BMGF) for useful discussions and feedback on the manuscript and David Foley (Dundee University) for providing insights on peptide transporters. We also gratefully acknowledge the support given to this work to P.W.S. by the University of Dundee.",
year = "2018",
month = "10",
day = "12",
doi = "10.1021/acsinfecdis.8b00160",
language = "English",
volume = "4",
pages = "1439--1447",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "10",

}

Pharmacokinetics of β-Lactam Antibiotics : Clues from the Past to Help Discover Long-Acting Oral Drugs in the Future. / Smith, Paul W.; Zuccotto, Fabio; Bates, Robert H.; Martinez-Martinez, Maria Santos; Read, Kevin D.; Peet, Caroline; Epemolu, Ola.

In: ACS Infectious Diseases, Vol. 4, No. 10, 12.10.2018, p. 1439-1447.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of β-Lactam Antibiotics

T2 - Clues from the Past to Help Discover Long-Acting Oral Drugs in the Future

AU - Smith, Paul W.

AU - Zuccotto, Fabio

AU - Bates, Robert H.

AU - Martinez-Martinez, Maria Santos

AU - Read, Kevin D.

AU - Peet, Caroline

AU - Epemolu, Ola

N1 - The authors gratefully acknowledge funding provided for this work by the Bill and Melinda Gates Foundation (BMGF, supporting P.W.S.) and the Wellcome Trust (Centre Award 203134/Z/16/Z supporting F.Z., K.D.R., C.P., and O.E.; Grant Award 100195/Z/12/Z supporting F.Z.). The authors would like to thank John Dixon (JD International Consulting Ltd) and Peter Warner (BMGF) for useful discussions and feedback on the manuscript and David Foley (Dundee University) for providing insights on peptide transporters. We also gratefully acknowledge the support given to this work to P.W.S. by the University of Dundee.

PY - 2018/10/12

Y1 - 2018/10/12

N2 - β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.

AB - β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.

KW - carbapenem

KW - cephalosporin

KW - M. tuberculosis

KW - penicillin

KW - pharmacokinetics

KW - β-lactam

UR - http://www.scopus.com/inward/record.url?scp=85053299763&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.8b00160

DO - 10.1021/acsinfecdis.8b00160

M3 - Article

C2 - 30141902

AN - SCOPUS:85053299763

VL - 4

SP - 1439

EP - 1447

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 10

ER -